Outcomes of Patients with Esophageal Squamous Cell Carcinoma Who Achieved a Pathological Complete Response in the Primary Lesion by Neoadjuvant Treatment: a Japanese Nationwide Cohort Study

Overview

Journal Esophagus

Publisher Springer

Specialties Gastroenterology
Oncology

Date 2023 Nov 24

PMID 37999900

Authors

Akihiko Okamura

Masayuki Watanabe

Jun Okui

Satoru Matsuda

Ryo Takemura

Hirofumi Kawakubo

Yoshihiro Kakeji

Koji Kono

Yuko Kitagawa

Hiroya Takeuchi

Affiliations

Soon will be listed here.

Abstract

Background: Minimal data was reported regarding the characteristics, risks of lymph node metastasis, and prognostic factors in esophageal cancer patients who achieved remarkable response in the primary lesion to neoadjuvant treatment (NAT).

Methods: This study evaluated the nationwide data of esophageal squamous cell carcinoma (ESCC) patients who underwent surgery following NAT in Japan. Of 4484 patients, 300 (6.7%) had ypT0 following NAT and curative esophagectomy. Factors associated with lymph node metastasis and prognosis were analyzed.

Results: Neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACRT) were administered in 260 (86.2%) and 40 (13.8%) patients, respectively. Pathologically, 72 (24.0%) had lymph node metastasis (residual nodal disease; RND), and pretherapeutic lymph node metastasis was the independent risk factor for RND (odd ratio [OR]: 3.21; 95% confidence interval [CI]: 1.44-8.20; P = 0.008). The 5-year overall and relapse-free survivals were significantly longer in patients with pathological complete response (pCR) than in those with RND (both P < 0.001). Pretherapeutic cT3 or T4a tumors (hazard ratio [HR]: 1.71; 95% CI: 1.02-2.88; P = 0.043), RND (HR: 3.30; 95% CI: 1.98-5.50; P < 0.001), and operative blood loss (Liter, HR: 1.53; 95% CI: 1.07-2.19; P = 0.021) were independent risk factors affecting relapse-free survival in multivariable analysis.

Conclusions: Of patients with ypT0 after NAT, 24.0% had RND, and pretherapeutic lymph node metastasis was the risk factor. In addition, pretherapeutic cT3, or T4a tumors, RND, and operative blood loss were the poor prognosticators in patients with ypT0 after NAT.

Citing Articles

Lymph-node ratio as a risk factor for recurrence following neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma.

Tamba M, Okamura A, Osumi H, Imamura Y, Kanamori J, Ogura M Esophagus. 2025; .

PMID: 39755858 DOI: 10.1007/s10388-024-01103-6.

A propensity score-matched comparison of neoadjuvant chemoradiotherapy with cisplatin-5FU and carboplatin-paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study.

Gurler F, Tay F, Isleyen Z, Yerlikaya T, Hendem E, Akturk Esen S Cancer Med. 2024; 13(14):e70002.

PMID: 39030808 PMC: 11257995. DOI: 10.1002/cam4.70002.

Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery.

Kim J, Yun J, Kim Y, Park S, Lee J, Jung H Ann Surg Oncol. 2024; 31(10):6662-6672.

PMID: 38954089 DOI: 10.1245/s10434-024-15678-y.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Cunningham D, Allum W, Stenning S, Thompson J, van de Velde C, Nicolson M . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11-20. DOI: 10.1056/NEJMoa055531. View

Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H . A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2011; 19(1):68-74. DOI: 10.1245/s10434-011-2049-9. View

van Hagen P, Hulshof M, van Lanschot J, Steyerberg E, van Berge Henegouwen M, Wijnhoven B . Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22):2074-84. DOI: 10.1056/NEJMoa1112088. View

Shapiro J, van Lanschot J, Hulshof M, van Hagen P, van Berge Henegouwen M, Wijnhoven B . Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015; 16(9):1090-1098. DOI: 10.1016/S1470-2045(15)00040-6. View

Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z . Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol. 2018; 36(27):2796-2803. PMC: 6145832. DOI: 10.1200/JCO.2018.79.1483. View

Saeki H, Sohda M, Sakai M, Sano A, Shirabe K . Role of surgery in multidisciplinary treatment strategies for locally advanced esophageal squamous cell carcinoma. Ann Gastroenterol Surg. 2020; 4(5):490-497. PMC: 7511562. DOI: 10.1002/ags3.12364. View

Sjoquist K, Burmeister B, Smithers B, Zalcberg J, Simes R, Barbour A . Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011; 12(7):681-92. DOI: 10.1016/S1470-2045(11)70142-5. View

Noordman B, Wijnhoven B, Lagarde S, Boonstra J, Coene P, Dekker J . Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. BMC Cancer. 2018; 18(1):142. PMC: 5801846. DOI: 10.1186/s12885-018-4034-1. View

10.

Noordman B, Spaander M, Valkema R, Wijnhoven B, van Berge Henegouwen M, Shapiro J . Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol. 2018; 19(7):965-974. DOI: 10.1016/S1470-2045(18)30201-8. View

11.

Aoyama J, Kawakubo H, Mayanagi S, Fukuda K, Irino T, Nakamura R . Discrepancy Between the Clinical and Final Pathological Findings of Lymph Node Metastasis in Superficial Esophageal Cancer. Ann Surg Oncol. 2019; 26(9):2874-2881. DOI: 10.1245/s10434-019-07498-2. View

12.

Chao Y, Chan S, Liu Y, Chen H, Wan Y, Chang H . Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy. Ann Surg. 2009; 249(3):392-6. DOI: 10.1097/SLA.0b013e3181949e9f. View

13.

Luc G, Gronnier C, Lebreton G, Brigand C, Mabrut J, Bail J . Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study. Ann Surg Oncol. 2015; 22 Suppl 3:S1357-64. DOI: 10.1245/s10434-015-4619-8. View

14.

La Mendola R, Bencivenga M, Torroni L, Alberti L, Sacco M, Casella F . Pretreatment Primary Tumor Stage is a Risk Factor for Recurrence in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response After Neoadjuvant Chemoradiotherapy. Ann Surg Oncol. 2020; 28(6):3034-3043. PMC: 8119402. DOI: 10.1245/s10434-020-09219-6. View

15.

Cools-Lartigue J, Markar S, Mueller C, Hofstetter W, Nilsson M, Ilonen I . An International Cohort Study of Prognosis Associated With Pathologically Complete Response Following Neoadjuvant Chemotherapy Versus Chemoradiotherapy of Surgical Treated Esophageal Adenocarcinoma. Ann Surg. 2022; 276(5):799-805. DOI: 10.1097/SLA.0000000000005619. View

16.

Clavien P, Barkun J, De Oliveira M, Vauthey J, Dindo D, Schulick R . The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009; 250(2):187-96. DOI: 10.1097/SLA.0b013e3181b13ca2. View

17.

Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H . Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2018; 16(1):1-24. PMC: 6510883. DOI: 10.1007/s10388-018-0641-9. View

18.

Kitagawa Y, Matsuda S . Prevention of postoperative pulmonary complication is desired to reduce mortality and improve long-term survival after esophagectomy for esophageal cancer. Ann Gastroenterol Surg. 2020; 4(5):478-479. PMC: 7511554. DOI: 10.1002/ags3.12391. View

19.

Shinozaki H, Matsuoka T, Ozawa S . Pharmacological treatment to reduce pulmonary morbidity after esophagectomy. Ann Gastroenterol Surg. 2021; 5(5):614-622. PMC: 8452480. DOI: 10.1002/ags3.12469. View

20.

Kikuchi H, Endo H, Yamamoto H, Ozawa S, Miyata H, Kakeji Y . Impact of Reconstruction Route on Postoperative Morbidity After Esophagectomy: Analysis of Esophagectomies in the Japanese National Clinical Database. Ann Gastroenterol Surg. 2022; 6(1):46-53. PMC: 8786683. DOI: 10.1002/ags3.12501. View